Want to see GYRE full AI Analyst Report?
GYRE Stock Chart & Stats
$5.94
-$0.07(-1.16%)
At close: 4:00 PM EDT
$5.94
-$0.07(-1.16%)
Day’s Range― - ―
52-Week Range$5.44 - $9.42
Previous Close$5.94
Volume33.77K
Average Volume (3M)102.52K
Market Cap
$732.69M
Enterprise Value$648.81
Total Cash (Recent Filing)$74.80M
Total Debt (Recent Filing)$3.42M
Price to Earnings (P/E)―
Beta1.75
Next Earnings
Nov 18, 2026EPS Estimate
-0.12Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.20
Shares Outstanding106,033,760
10 Day Avg. Volume112,833
30 Day Avg. Volume102,519
Financial Highlights & Ratios
PEG Ratio-2.10
Price to Book (P/B)5.95
Price to Sales (P/S)5.41
P/FCF Ratio-3.50K
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$19.00Price Target Upside219.87% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.29
Revenue Forecast (FY)$102.30M
Bulls Say, Bears Say
Bulls Say
Very High Gross MarginsSustained ~94% gross margins indicate strong product economics and pricing power typical in biopharma, allowing Gyre to absorb R&D and SG&A as it scales. Over the next 2–6 months this margin cushion supports pipeline investment, licensing leverage and commercial rollout resilience.
Conservative Balance Sheet And Low LeverageExtremely low leverage and meaningful equity provide durable financial flexibility to fund clinical programs, integrate acquisitions and withstand biotech volatility. This reduces near-term refinancing risk and supports strategic choices (e.g., Cullgen deal, China expansion) over coming quarters.
Pipeline Expansion And China Regulatory ProgressThe Cullgen acquisition and China-focused R&D strategy materially diversify Gyre's pipeline into protein degraders and DACs while leveraging lower-cost development. Combined with F351 NDA priority review in China, this structural progress increases addressable markets and commercial optionality over the medium term.
Bears Say
Return To TTM Net LossReversion from prior-year profitability to a TTM net loss weakens earnings durability and reduces internal funding for trials and commercialization. Persistent losses over the next 2–6 months raise the probability of equity dilution or greater reliance on external capital, stressing long-term ROE.
Uneven Operating Cash FlowNegative operating cash flow and an inconsistent historical cash profile suggest timing and working-capital pressures that can impair reliable funding of clinical programs. Even with recent positive free cash flow, unreliable OCF raises execution risk and could force financing at inopportune times.
Commercial Concentration And Generic CompetitionHeavy reliance on the ETUARY franchise exposes revenue to pricing and volume pressure from generic pirfenidone entrants. Sustained generics competition plus the need to prove new indications increases commercial and clinical execution risk that can erode margins and growth durability over months.
Gyre Therapeutics News
GYRE FAQ
What was Gyre Therapeutics’s price range in the past 12 months?
Gyre Therapeutics lowest stock price was $5.44 and its highest was $9.42 in the past 12 months.
What is Gyre Therapeutics’s market cap?
Gyre Therapeutics’s market cap is $732.69M.
When is Gyre Therapeutics’s upcoming earnings report date?
Gyre Therapeutics’s upcoming earnings report date is Nov 18, 2026 which is in 85 days.
How were Gyre Therapeutics’s earnings last quarter?
Gyre Therapeutics released its earnings results on Aug 07, 2026. The company reported -$0.12 earnings per share for the quarter, missing the consensus estimate of -$0.057 by -$0.063.
Is Gyre Therapeutics overvalued?
According to Wall Street analysts Gyre Therapeutics’s price is currently Undervalued.
Does Gyre Therapeutics pay dividends?
Gyre Therapeutics pays a Quarterly dividend of $3.6 which represents an annual dividend yield of N/A. See more information on Gyre Therapeutics dividends here
What is Gyre Therapeutics’s EPS estimate?
Gyre Therapeutics’s EPS estimate is -0.12.
How many shares outstanding does Gyre Therapeutics have?
Gyre Therapeutics has 106,033,760 shares outstanding.
What happened to Gyre Therapeutics’s price movement after its last earnings report?
Gyre Therapeutics reported an EPS of -$0.12 in its last earnings report, missing expectations of -$0.057. Following the earnings report the stock price went up 4.219%.
Which hedge fund is a major shareholder of Gyre Therapeutics?
Currently, no hedge funds are holding shares in GYRE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Gyre Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$19.00 (219.87% Upside)
$19.00 (219.87% Upside)
Insider Transactions
Sold Shares
Worth $869.9K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▼ 5.1%
Last 30 Days ▼ 5.1%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-40.79%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
30.53%
Trailing 12-Months
Company Description
Gyre Therapeutics
Gyre Therapeutics, Inc. is a pharmaceutical company dedicated to discovering, advancing, and bringing to market small-molecule drugs that target inflammation and fibrosis in various organs. The company's key anti-fibrotic medication, ETUARY (Pirfenidone), has received approval for treating idiopathic pulmonary fibrosis. Beyond this, ETUARY is also undergoing late-stage (Phase 3) clinical trials for several other conditions, including dermatomyositis and interstitial lung disease linked to systemic sclerosis, pneumoconiosis, and diabetic kidney disease. The company's pipeline further includes F351 (Hydronidone), a compound structurally related to ETUARY. F351 is currently in Phase 3 studies for chronic hepatitis B-induced liver fibrosis and is in Phase 1 trials for liver fibrosis associated with nonalcoholic associated steatohepatitis (NASH). Other programs in development feature F573, which is progressing through Phase 2 studies for acute and acute-on-chronic liver failure. Additionally, two early-stage candidates, F528 and F230, are in preclinical development, focusing on chronic obstructive pulmonary disease (COPD) and pulmonary arterial hypertension (PAH), respectively. Established in 2002, Gyre Therapeutics, Inc. is based in San Diego, California, and operates as a subsidiary of GNI USA, Inc.
GYRE Stock 12 Month Forecast
Average Price Target
$19.00
▲(219.87% Upside)
Technical Analysis
Ownership Overview
63.46% Insiders
1.46% Mutual Funds
4.45% Other Institutional Investors
28.99% Public Companies and
Individual Investors